• Intellia Therapeutics reported that the FDA accepted its BLA for lonvo-z, granted Priority Review without planning an advisory committee, and based the filing on positive Phase 3 HAELO data showing an 87% reduction in hereditary angioedema attacks after a single 50 milligram dose.
• The company also secured a non-dilutive senior secured term loan facility of up to $400 million, structured around lonvo-z regulatory, revenue and fundraising milestones, which ties future access to capital directly to the therapy’s commercial progress.
• This article examines how Intellia Therapeutics’ investment narrative is shaped by lonvo-z’s Priority Review and the milestone-linked $400 million financing.

Scan beyond Intellia Therapeutics and see how…